Nurami Medical

Modernizing Soft Tissue Repair

Health Tech & Life Sciences
Active
Series B Haifa Founded 2014
Total raised
$43.6M
Last: Undisclosed 2025-03
Stage
Series B
Founded
2014
Headcount
28
HQ
Haifa
Sector
Health Tech & Life Sciences

About

Nurami harnesses nanofibers and novel biomaterials to modernize soft tissue surgical repair. Nurami’s proprietary, electrospun-based platform technology enables the creation of an innovative category of bio surgical implants to seal and heal wounds effectively. These advanced products address complications associated with current soft tissue implants, such as dangerous leaks, and promote healthy tissue formation such as Dura repair as well as other tissue recovery processes.

Nurami's first soft-tissue repair product, ArtiFascia, is a multilayer, Dural repair graft made of biocompatible and bioabsorbable polymers with integrated barrier layer and a biomimetic structure of electrospun fibers designed to promote neodura regeneration. ArtiFascia is available for commercial use in the USA and has FDA 510(k) clearance.

Funding history · 4 rounds · $43.6M total

2025-03
Undisclosed $30.0M
2020-11
Series B $6.0M
2018-07
Series A $2.0M
2016-12
Seed $1.7M

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringMedical DevicesMedical Treatment & Therapeutics
Technologies
Materials & SubstancesNanomaterialsPolymersImplants
Target customers
Healthcare & Life SciencesHealthcareProvidersLife SciencesBiotechnology
Business model
B2B

Highlights

1 PatentsVerified

Tags

surgeonsbiodegradablenanotechnologysurgeryneurologydoctorshospitalsmedical-technologiesregenerative-medicinefibersneurosurgerylife-sciencesmedical-devicesbiotechnologybiomaterialstissue-regeneration